<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="ame270035" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Animal Model Exp Med</journal-id><journal-id journal-id-type="iso-abbrev">Animal Model Exp Med</journal-id><journal-id journal-id-type="pmc-domain-id">3615</journal-id><journal-id journal-id-type="pmc-domain">animalmod</journal-id><journal-id journal-id-type="publisher-id">AME2</journal-id><journal-title-group><journal-title>Animal Models and Experimental Medicine</journal-title></journal-title-group><issn pub-type="ppub">2096-5451</issn><issn pub-type="epub">2576-2095</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12431587</article-id><article-id pub-id-type="pmcid-ver">PMC12431587.1</article-id><article-id pub-id-type="pmcaid">12431587</article-id><article-id pub-id-type="pmcaiid">12431587</article-id><article-id pub-id-type="pmid">40534105</article-id><article-id pub-id-type="doi">10.1002/ame2.70035</article-id><article-id pub-id-type="publisher-id">AME270035</article-id><article-id pub-id-type="other">AMEM-2024-0375.R5</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Themed Section: Mechanism Verification of Plant Bioactive Components</subject><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></subj-group></article-categories><title-group><article-title>Protective effects of allicin against stanozolol&#8208;induced cardiotoxicity: Physiological and histopathological evidence in a rabbit model</article-title><alt-title alt-title-type="left-running-head">Asker et&#160;al.</alt-title></title-group><contrib-group><contrib id="ame270035-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Asker</surname><given-names initials="MH">Mohammed Hayder</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0009-5767-2522</contrib-id><xref rid="ame270035-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>moh.hayder@uomustansiriyah.edu.iq</email></address></contrib><contrib id="ame270035-cr-0002" contrib-type="author"><name name-style="western"><surname>AL&#8208;Zuhairy</surname><given-names initials="NALHS">Noor AL&#8208;Huda Salah</given-names></name><xref rid="ame270035-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="ame270035-cr-0003" contrib-type="author"><name name-style="western"><surname>Husain</surname><given-names initials="WM">Wassan Mhammed</given-names></name><xref rid="ame270035-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="ame270035-cr-0004" contrib-type="author"><name name-style="western"><surname>Abdullah</surname><given-names initials="MR">Mustafa Riyadh</given-names></name><xref rid="ame270035-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="ame270035-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Pharmacology and Toxicology, College of Pharmacy</named-content>
<institution>Mustansiriyah University Baghdad</institution>
<city>Baghdad</city>
<country country="IQ">Iraq</country>
</aff><aff id="ame270035-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Medical College</named-content>
<institution>Ibn Sina University of Medical and Pharmaceutical Sciences</institution>
<city>Baghdad</city>
<country country="IQ">Iraq</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Mohammed Hayder Asker, Department of Pharmacology and Toxicology, College of Pharmacy, Mustansiriyah University Baghdad, Baghdad, Iraq.<break/>
Email: <email>moh.hayder@uomustansiriyah.edu.iq</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>6</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>7</month><year>2025</year></pub-date><volume>8</volume><issue seq="60">7</issue><issue-id pub-id-type="pmc-issue-id">496817</issue-id><issue-id pub-id-type="doi">10.1002/ame2.v8.7</issue-id><issue-title content-type="special-issue-title">Themed Issue: Mechanism Verification of Plant Bioactive Components</issue-title><fpage>1196</fpage><lpage>1205</lpage><history><date date-type="received"><day>24</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>09</day><month>5</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>18</day><month>06</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 17:25:36.317"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Animal Models and Experimental Medicine</italic> published by John Wiley &amp; Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="AME2-8-1196.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:AME2-8-1196.pdf"/><abstract><title>Abstract</title><sec id="ame270035-sec-1001"><title>Background</title><p>There are many forms of anabolic steroids, including stanozolol (Winstrol), which are popular for their muscle&#8208;building effects but dangerous to the heart. This present work is aimed at evaluating the pharmacologica impact of allicin, a natural attribute obtained from garlic, on obstructing cardiac injury in rabbits that received stanozolol.</p></sec><sec id="ame270035-sec-1002"><title>Methods</title><p>Thirty rabbits were divided into three groups: control, stanozolol&#8208;treated, and stanozolol plus allicin. Cardiac function was assessed by measuring troponin, creatine kinase (CK), Galectin&#8208;3, and GDF&#8208;15. Oxidative stress and antioxidant markers, including malondialdehyde (MDA), glutathione, and catalase, were analyzed. Inflammatory mediators such as C&#8208;reactive protein (CRP), interleukin&#8208;6 (IL&#8208;6), NF&#8208;&#954;B, iNOS, nitric oxide (NO), tumor necrosis factor&#8208;alpha (TNF&#8208;&#945;), and interleukin&#8208;1 beta (IL&#8208;1&#946;) were evaluated. Lipid profile parameters, including total cholesterol, low&#8208;density lipoprotein (LDL), and high&#8208;density lipoprotein (HDL), were measured. Histopathological examination assessed myocardial damage, fibrosis, and collagen deposition.</p></sec><sec id="ame270035-sec-1003"><title>Results</title><p>Stanozolol administration significantly increased cardiac damage markers, oxidative stress, and inflammatory mediators while causing dyslipidemia, characterized by elevated LDL and total cholesterol and reduced HDL. Allicin co&#8208;administration effectively countered these effects by reducing oxidative stress and inflammation, restoring antioxidant balance, and improving lipid profiles. Histopathological analysis revealed severe myocardial disorganization, necrosis, and fibrosis in the stanozolol group, whereas the allicin&#8208;treated group exhibited preserved myocardial structure with reduced collagen deposition.</p></sec><sec id="ame270035-sec-1004"><title>Conclusion</title><p>Allicin significantly mitigates stanozolol&#8208;induced cardiotoxicity by reducing oxidative stress, inflammation, lipid dysregulation, and myocardial damage, as evidenced by biochemical and histopathological findings. These results suggest that allicin may serve as a potential therapeutic agent to counteract the cardiovascular risks associated with anabolic steroid use.</p></sec></abstract><abstract abstract-type="graphical"><p>There are many forms of anabolic steroids, including stanzolo (Winstrol), which are popular for their muscle&#8208;building effects but dangerous to the heart. This present work is aimed at evaluating the pharmacological impact of allacin, a natural attribute obtained from garlic on obstructing cardiac injury in rabbits that received stanzolo. A total of 30 rabbits were divided into three groups: control, stanzolo&#8208;treated and Stanzolo plus Allacin. Chemical parameters comprised of C&#8208;reactive protein (CRP) serum, malondialdehyde (MDA), glutathione, troponin and cardiac enzymes were measured biochemically to test the cardiac dysfunction and oxidative stress after 30&#8201;days of practice. Another investigation carried out in relation to the structural cardiac changes involved histopathological evaluation. Findings revealed that, relative to placebo, stanzolo upregulated the levels of inflammation marker CRP, lipid peroxidation marker MDA, and cardiac troponin, and &#8216;downregulated the antioxidant glutathione&#8217;. On the other hand, rabbits in the allacin&#8208;treated group had lower levels of these markers, which meant a possible cardioprotection against exogenous steroids. Biochemical results were also for the most part echoed by histopathological changes which revealed better preserved myofiber structure and less myocardial damage in allacin treated animals compared with stanzolo treated rats. The current research highlights allacin as a possible protective agent against anabolic steroid induced cardiovascular toxicity, offering important findings about therapeutic approach in steroid consumers.<boxed-text position="anchor" content-type="graphic" id="ame270035-blkfxd-0001" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="AME2-8-1196-g004.jpg"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="ame270035-kwd-0001">anabolic steroids</kwd><kwd id="ame270035-kwd-0002">antioxidants</kwd><kwd id="ame270035-kwd-0003">cardiovascular diseases</kwd><kwd id="ame270035-kwd-0004">oxidative stress</kwd><kwd id="ame270035-kwd-0005">rabbit model</kwd></kwd-group><counts><fig-count count="4"/><table-count count="6"/><page-count count="10"/><word-count count="6500"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>July 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.2 mode:remove_FC converted:12.09.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="AME270035-cit-2001"><string-name name-style="western"><surname>Asker</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>AL&#8208;Zuhairy</surname><given-names>N&#8208;H</given-names></string-name>, <string-name name-style="western"><surname>Husain</surname><given-names>WM</given-names></string-name>, <string-name name-style="western"><surname>Abdullah</surname><given-names>MR</given-names></string-name>. <article-title>Protective effects of allicin against stanozolol&#8208;induced cardiotoxicity: Physiological and histopathological evidence in a rabbit model</article-title>. <source>Anim Models Exp Med</source>. <year>2025</year>;<volume>8</volume>:<fpage>1196</fpage>&#8208;<lpage>1205</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ame2.70035</pub-id><pub-id pub-id-type="pmcid">PMC12431587</pub-id><pub-id pub-id-type="pmid">40534105</pub-id></mixed-citation>
</p></notes></front><body id="ame270035-body-0001"><sec id="ame270035-sec-0001"><label>1</label><title>INTRODUCTION</title><p>Stanzolo, or Winstrol, is an anabolic steroid that belongs to the group of drugs that have a hormonal structure and is based on testosterone, which is useful in the practice of sports medicine due to the given effect. Though they can enhance muscular development and ramp up exercise capacity, they are linked to various side effects most relating to the cardiovascular system. An amount of literature is available on the cardiotoxic effect of anabolic steroids in various population groups and has pointed to the anabolic steroids' ability to cause myocardial injury, dyslipidemia, and changes in speckle tracking&#8208;based measures of cardiac function.<xref rid="ame270035-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="ame270035-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> Some of the processes that explain these adverse effects cover the following: increased levels of oxidative stress and inflammation and altered guidelines of cardiac biomarkers, which affect the overall integrity and function of the cardiac tissues.<xref rid="ame270035-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="ame270035-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>
</p><p>It has been postulated that oxidative stress is the main link in the causal chain of steroid&#8208;induced cardiotoxicity. Reactive oxygen species (ROS) production that is closely associated with lipid peroxidation and myocardial damage has also been implicated with anabolic steroids.<xref rid="ame270035-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> The oxidative stress in addition to adversely affecting cellular functioning also activates inflammatory responses, which in turn makes a worse cardiac damage.<xref rid="ame270035-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> Therefore, the present study hypothesized that there are increased systemic inflammations as shown by the levels of C&#8208;reactive protein (CRP) and interleukin&#8208;6 (IL&#8208;6) that can worsen cardiovascular outcomes.<xref rid="ame270035-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>
</p><p>Due to the side effects the anabolic steroids produce on the cardiovascular system different protective approaches have been investigated to power anabolic steroids including the use of natural compounds with scouring antioxidant and anti&#8208;inflammatory properties. It has a role in antioxidant activities and cardiovascular health, a fact which has made such substances as Allicin found in garlic gain attention for cardioprotective properties.<xref rid="ame270035-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="ame270035-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> Earlier trials have shown that allicin could decrease levels of oxidative diseases and dysfunction of the endothelial layer, which implies the possibility of using this agent in treating cardiovascular pathology.<xref rid="ame270035-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>
</p><p>The purpose of this present work is to determine the beneficial physiological role of allicin in protecting rabbits subjected to stanozol&#8208;induced cardiotoxicity. In addition, efforts will be made to relate these biochemical changes to histopathological alterations in cardiac tissue. Thus, the present study aims to cast light on the ability of allicin to prevent anabolic steroid&#8208;elicited cardiotoxicity.</p></sec><sec sec-type="methods" id="ame270035-sec-0002"><label>2</label><title>METHODS</title><sec id="ame270035-sec-0003"><label>2.1</label><title>Animal preparation and experimental design</title><p>A total of 30 adult male rabbits, weighing approximately 2.5 to 3.0&#8201;kg, were housed under controlled conditions with a 12&#8208;h light&#8211;dark cycle and ad&#160;libitum access to food and water. The experimental animals received two weeks to acclimate before the study initiation. The protocol received approval from the Institutional Animal Care and Use Committee of [Mustansiriyah University] under reference number [No: 42 on 1/9/2024] to ensure ethical guidelines protecting animal well&#8208;being.</p><p>Research subjects received distribution across three separate groups:
<list list-type="bullet" id="ame270035-list-0001"><list-item id="ame270035-li-0001"><p>Control Group (<italic toggle="yes">n</italic>&#8201;=&#8201;10): Rabbits received no treatment or received a placebo injection.</p></list-item><list-item id="ame270035-li-0002"><p>Stanozolol Group (<italic toggle="yes">n</italic>&#8201;=&#8201;10): Rabbits were treated with Stanozolol (Winstrol) at a dosage of 0.5&#8201;mg/kg body weight for 30&#8201;days.<xref rid="ame270035-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>
</p></list-item><list-item id="ame270035-li-0003"><p>Allicin&#8201;+&#8201;Stanozolol Group (<italic toggle="yes">n</italic>&#8201;=&#8201;10): Rabbits received a 0.5&#8201;mg/kg body weight Stanozolol (Winstrol) dosage together with a 20&#8201;mg/kg body weight allicin dose for 30&#8201;days according to Shaikh.<xref rid="ame270035-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>
</p></list-item></list>
</p></sec><sec id="ame270035-sec-0004"><label>2.2</label><title>Biochemical marker analysis</title><p>Blood samples were collected from each rabbit at baseline and the end of the treatment period for biochemical analyses. Blood samples were collected from each animal via the jugular vein. Blood samples were centrifuged at 3000 revolutions per minute (rpm) for 15&#8201;min, and serum was collected and stored at &#8722;20&#176;C until analysis. The following biomarkers were analyzed.</p><sec id="ame270035-sec-0005"><label>2.2.1</label><title>Cardiac damage markers</title><p>Troponin and Creatinine Kinase (CK) levels were measured using enzyme&#8208;linked immunosorbent assay (ELISA) kits (abcam, ab200016, ab285275) as per the manufacturer's instructions.</p><p>Galectin&#8208;3 and Growth Differentiation Factor&#8208;15 (GDF&#8208;15) levels were quantified using specific ELISA assays (E&#8208;EL&#8208;H1470, RayBio&#174;).</p></sec><sec id="ame270035-sec-0006"><label>2.2.2</label><title>Oxidative stress and antioxidant markers</title><p>Levels of MDA, Glutathione, and Catalase were assessed using colorimetric methods. MDA levels were measured based on the thiobarbituric acid reactive substances (TBARS) assay (Solarbio Science &amp; Technology Co., Ltd).</p></sec><sec id="ame270035-sec-0007"><label>2.2.3</label><title>Lipid profile</title><p>Total cholesterol, Low&#8208;Density Lipoprotein (LDL), and High&#8208;Density Lipoprotein (HDL) levels were analyzed using enzymatic methods and commercially available kits (LINEAR CHEMICALS S.L.).</p></sec><sec id="ame270035-sec-0008"><label>2.2.4</label><title>Inflammatory markers</title><p>CRP, IL&#8208;6, procalcitonin, and aspartate aminotransferase (AST) were assessed using ELISA kits according to the manufacturer's protocols (Abcam, ab260058, ab178013, ab100630, ab263881).</p></sec><sec id="ame270035-sec-0009"><label>2.2.5</label><title>Damage markers</title><p>Blood samples were collected and processed to evaluate damage markers, including NF&#8208;&#954;B, iNOS, NO, Bcl&#8208;2, Caspase&#8208;3, TNF&#8208;&#945;, and IL&#8208;1&#946;. Enzyme&#8208;linked immunosorbent assay (ELISA) was used to quantify NF&#8208;&#954;B (ab176648&#8212;Abcam), Bcl&#8208;2 (ab119506&#8212;Abcam), Caspase&#8208;3 (# BMS2012INST&#8212;Thermo Fisher Scientific Inc), TNF&#8208;&#945; (# KHC3011&#8212;Thermo Fisher Scientific Inc), and IL&#8208;1&#946; levels (# KHC0011&#8212;Thermo Fisher Scientific Inc), while iNOS activity and NO concentration were measured using spectrophotometric assays (AB5384&#8212;Millipore).</p></sec></sec><sec id="ame270035-sec-0010"><label>2.3</label><title>Histopathological examination</title><p>Following biochemical analysis, all animals were euthanized by an overdose of anesthesia (ketamine/xylazine), and heart tissues were harvested. Samples were fixed in 10% buffered formalin for 24&#8211;48&#8201;h, dehydrated through graded alcohols, embedded in paraffin, and sectioned at 4&#8211;5&#8201;&#956;m thickness.</p><p>The scoring system parameters,</p><p>Each parameter was scored on a scale of 0 to 3, as follows:
<list list-type="simple" id="ame270035-list-0002"><list-item id="ame270035-li-0004"><p>0: No detectable abnormality.</p></list-item><list-item id="ame270035-li-0005"><p>1: Mild changes (e.g., scattered inflammatory cells or slight disarray).</p></list-item><list-item id="ame270035-li-0006"><p>2: Moderate changes (e.g., focal necrosis or moderate fibrosis).</p></list-item><list-item id="ame270035-li-0007"><p>3: Severe changes (e.g., extensive necrosis or widespread fibrosis).</p></list-item></list>
</p><p>The complete measure of cardiovascular tissue injury used the combination of scores from all evaluation criteria to assess the extent of myocardial damage.<xref rid="ame270035-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>
</p><p>Left ventricle collagen deposition received assessment using biomedical and histological techniques. The histology examination required heart tissue fixation through 10% neutral&#8208;buffered formalin while the paraffin embedding was followed by sectioning at 5&#8201;&#956;m thickness. Masson's trichrome staining allowed researchers to view collagen fibers in cardiac tissue specimens.</p></sec><sec id="ame270035-sec-0011"><label>2.4</label><title>Relative heart weight</title><p>The relative heart weight (RHW) value was calculated as follows equation<xref rid="ame270035-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>:<disp-formula id="ame270035-disp-0001"><mml:math id="jats-math-1" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>RHW</mml:mi><mml:mo linebreak="goodbreak">=</mml:mo><mml:mtext>Heart Weight</mml:mtext><mml:mspace width="0.25em"/><mml:mfenced close=")" open="("><mml:mi mathvariant="normal">g</mml:mi></mml:mfenced><mml:mo>/</mml:mo><mml:mtext>Body Weight</mml:mtext><mml:mspace width="0.25em"/><mml:mfenced close=")" open="("><mml:mi>kg</mml:mi></mml:mfenced></mml:mrow></mml:mrow></mml:math></disp-formula>
</p></sec><sec id="ame270035-sec-0012"><label>2.5</label><title>Statistical analysis</title><p>The research data received analysis through Statistical Package for the Social Sciences (SPSS version 26). All variables received descriptive statistical analysis and one&#8208;way ANOVA provided group mean comparison and analysis. The data analysis conducted a Tukey's HSD test for post hoc evaluation. Results with a statistical significance at <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 were determined to be valid.</p></sec></sec><sec sec-type="results" id="ame270035-sec-0013"><label>3</label><title>RESULTS</title><sec id="ame270035-sec-0014"><label>3.1</label><title>Cardiac damage markers</title><p>The three experimental groups had distinct troponin and CK levels along with Galectin&#8208;3 and GDF&#8208;15 levels which indicate different extents of cardiac injury. Compared to the control group, the stanozolol&#8208;only group exhibited significantly elevated levels of Troponin (0.5&#8201;&#177;&#8201;0.15&#8201;ng/mL) and CK (300&#8201;&#177;&#8201;20&#8201;U/L), indicative of cardiotoxicity due to stanozolol administration. Allicin treatment in the Stanozolol + Allicin group mitigated these elevations, with Troponin and CK levels reduced to 0.2&#8201;&#177;&#8201;0.1&#8201;ng/mL and 150&#8201;&#177;&#8201;15&#8201;U/L, respectively. This reduction was statistically significant, with <italic toggle="yes">p</italic>&#8208;values &lt;0.005 for Troponin and 0.002 for CK (Table&#160;<xref rid="ame270035-tbl-0001" ref-type="table">1</xref>).</p><table-wrap position="float" id="ame270035-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Cardiac damage markers in different experimental groups.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Marker</th><th align="left" valign="bottom" rowspan="1" colspan="1">Control group</th><th align="left" valign="bottom" rowspan="1" colspan="1">Stanozolol&#8208;only group</th><th align="left" valign="bottom" rowspan="1" colspan="1">Stanozolol&#8201;+&#8201;Allicin group</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8208;Value (control vs. stanozolol)</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8208;Value (stanozolol vs. allicin)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Troponin (ng/mL)</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">0.02&#8201;&#177;&#8201;0.01</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">0.5&#8201;&#177;&#8201;0.15</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">0.2&#8201;&#177;&#8201;0.1</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Creatinine kinase (U/L)</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">75&#8201;&#177;&#8201;10</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">300&#8201;&#177;&#8201;20</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">150&#8201;&#177;&#8201;15</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Galectin&#8208;3 (ng/mL)</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">5&#8201;&#177;&#8201;1</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">15&#8201;&#177;&#8201;3</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">8&#8201;&#177;&#8201;2</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GDF&#8208;15 (pg/mL)</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">500&#8201;&#177;&#8201;50</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">2000&#8201;&#177;&#8201;150</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">1200&#8201;&#177;&#8201;100</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.01</td></tr></tbody></table></table-wrap></sec><sec id="ame270035-sec-0015"><label>3.2</label><title>Oxidative stress and antioxidant defense markers</title><p>Markers of oxidative stress and antioxidant defense, including MDA, Glutathione, and Catalase, showed significant differences among the experimental groups. MDA levels increased from 1&#8201;&#177;&#8201;0.2&#8201;nmol/mL in the control group to 4&#8201;&#177;&#8201;0.5&#8201;nmol/mL in the stanozolol&#8208;only group, while the Stanozolol + Allicin group showed a reduction to 2&#8201;&#177;&#8201;0.3&#8201;nmol/mL (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, <italic toggle="yes">p</italic>&#8201;=&#8201;0.003). Glutathione levels decreased from 9&#8201;&#177;&#8201;1&#8201;&#956;mol/L in the control group to 4&#8201;&#177;&#8201;1&#8201;&#956;mol/L in the stanozolol&#8208;only group, with the Stanozolol + Allicin group showing levels of 8&#8201;&#177;&#8201;1&#8201;&#956;mol/L (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, <italic toggle="yes">p</italic>&#8201;=&#8201;0.01). Catalase activity dropped from 50&#8201;&#177;&#8201;5&#8201;U/mg in the control group to 20&#8201;&#177;&#8201;3&#8201;U/mg in the stanozolol&#8208;only group, with an increase to 40&#8201;&#177;&#8201;5&#8201;U/mg in the Stanozolol + Allicin group (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, <italic toggle="yes">p</italic>&#8201;=&#8201;0.005) (Table&#160;<xref rid="ame270035-tbl-0002" ref-type="table">2</xref>).</p><table-wrap position="float" id="ame270035-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Oxidative stress and antioxidant defense markers.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Marker</th><th align="left" valign="bottom" rowspan="1" colspan="1">Control group</th><th align="left" valign="bottom" rowspan="1" colspan="1">Stanozolol&#8208;only group</th><th align="left" valign="bottom" rowspan="1" colspan="1">Stanozolol&#8201;+&#8201;Allicin group</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8208;Value (control vs. stanozolol)</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8208;Value (stanozolol vs. allicin)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">MDA (nmol/mL)</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">1&#8201;&#177;&#8201;0.2</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">4&#8201;&#177;&#8201;0.5</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">2&#8201;&#177;&#8201;0.3</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Glutathione (&#956;mol/L)</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">9&#8201;&#177;&#8201;1</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">4&#8201;&#177;&#8201;1</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">8&#8201;&#177;&#8201;1</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Catalase (U/mg)</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">50&#8201;&#177;&#8201;5</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">20&#8201;&#177;&#8201;3</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">40&#8201;&#177;&#8201;5</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.005</td></tr></tbody></table></table-wrap></sec><sec id="ame270035-sec-0016"><label>3.3</label><title>Lipid profile</title><p>Increased Total Cholesterol and LDL levels in the stanozolol&#8208;only group (120&#8201;&#177;&#8201;10&#8201;mg/dL and 70&#8201;&#177;&#8201;5&#8201;mg/dL, respectively) compared to controls reflect lipid dysregulation due to stanozolol. Allicin co&#8208;administration resulted in significant improvements, reducing Total Cholesterol to 90&#8201;&#177;&#8201;8&#8201;mg/dL and LDL to 50&#8201;&#177;&#8201;4&#8201;mg/dL (<italic toggle="yes">p</italic>&#8208;values &lt;0.01 and 0.005, respectively), HDL levels, which were reduced in the stanozolol&#8208;only group (25&#8201;&#177;&#8201;3&#8201;mg/dL) compared to controls (40&#8201;&#177;&#8201;5&#8201;mg/dL, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), increased to 35&#8201;&#177;&#8201;4&#8201;mg/dL in the Stanozolol + Allicin group (<italic toggle="yes">p</italic>&#8201;=&#8201;0.01), as seen in Table&#160;<xref rid="ame270035-tbl-0003" ref-type="table">3</xref>.</p><table-wrap position="float" id="ame270035-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Lipid profile markers.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Marker</th><th align="left" valign="bottom" rowspan="1" colspan="1">Control group</th><th align="left" valign="bottom" rowspan="1" colspan="1">Stanozolol&#8208;only group</th><th align="left" valign="bottom" rowspan="1" colspan="1">Stanozolol&#8201;+&#8201;Allicin group</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8208;Value (control vs. stanozolol)</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8208;Value (stanozolol vs. allicin)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Total cholesterol (mg/dL)</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">70&#8201;&#177;&#8201;5</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">120&#8201;&#177;&#8201;10</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">90&#8201;&#177;&#8201;8</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LDL (mg/dL)</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">35&#8201;&#177;&#8201;3</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">70&#8201;&#177;&#8201;5</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">50&#8201;&#177;&#8201;4</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HDL (mg/dL)</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">40&#8201;&#177;&#8201;5</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">25&#8201;&#177;&#8201;3</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">35&#8201;&#177;&#8201;4</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.01</td></tr></tbody></table></table-wrap></sec><sec id="ame270035-sec-0017"><label>3.4</label><title>Inflammatory and organ damage markers</title><p>Markers of inflammation and organ damage, including CRP, IL&#8208;6, Procalcitonin, AST, and Cystatin C, showed significant changes across experimental groups. CRP levels increased from 0.5&#8201;&#177;&#8201;0.1&#8201;mg/L in the control group to 5&#8201;&#177;&#8201;0.5&#8201;mg/L in the stanozolol&#8208;only group, with a reduction to 2&#8201;&#177;&#8201;0.3&#8201;mg/L in the Stanozolol + Allicin group (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, <italic toggle="yes">p</italic>&#8201;=&#8201;0.01). Similarly, IL&#8208;6 levels rose from 2&#8201;&#177;&#8201;0.5&#8201;pg/mL in the control group to 15&#8201;&#177;&#8201;2&#8201;pg/mL in the stanozolol&#8208;only group and decreased to 7&#8201;&#177;&#8201;1&#8201;pg/mL with allicin co&#8208;administration (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, <italic toggle="yes">p</italic>&#8201;=&#8201;0.005). Procalcitonin increased from 0.05&#8201;&#177;&#8201;0.01&#8201;ng/mL in the control group to 0.5&#8201;&#177;&#8201;0.05&#8201;ng/mL in the stanozolol&#8208;only group, with a reduction to 0.2&#8201;&#177;&#8201;0.03&#8201;ng/mL in the Stanozolol + Allicin group (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, <italic toggle="yes">p</italic>&#8201;=&#8201;0.01). AST levels rose from 15&#8201;&#177;&#8201;2&#8201;U/L in the control group to 40&#8201;&#177;&#8201;5&#8201;U/L in the stanozolol&#8208;only group and were reduced to 25&#8201;&#177;&#8201;4&#8201;U/L with allicin treatment (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, <italic toggle="yes">p</italic>&#8201;=&#8201;0.005). Lastly, Cystatin C levels increased from 0.6&#8201;&#177;&#8201;0.05&#8201;mg/L in the control group to 1.2&#8201;&#177;&#8201;0.1&#8201;mg/L in the stanozolol&#8208;only group and decreased to 0.8&#8201;&#177;&#8201;0.08&#8201;mg/L in the Stanozolol + Allicin group (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, <italic toggle="yes">p</italic>&#8201;=&#8201;0.01). (Table&#160;<xref rid="ame270035-tbl-0004" ref-type="table">4</xref>).</p><table-wrap position="float" id="ame270035-tbl-0004" content-type="TABLE" orientation="portrait"><label>TABLE 4</label><caption><p>Inflammatory and organ damage markers &#8208; general biomarkers.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Marker</th><th align="left" valign="bottom" rowspan="1" colspan="1">Control group</th><th align="left" valign="bottom" rowspan="1" colspan="1">Stanozolol&#8208;only group</th><th align="left" valign="bottom" rowspan="1" colspan="1">Stanozolol&#8201;+&#8201;Allicin group</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8208;Value (control vs. stanozolol)</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8208;Value (stanozolol vs. allicin)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">CRP (mg/L)</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">0.5&#8201;&#177;&#8201;0.1</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">5&#8201;&#177;&#8201;0.5</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">2&#8201;&#177;&#8201;0.3</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IL&#8208;6 (pg/mL)</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">2&#8201;&#177;&#8201;0.5</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">15&#8201;&#177;&#8201;2</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">7&#8201;&#177;&#8201;1</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Procalcitonin (ng/mL)</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">0.05&#8201;&#177;&#8201;0.01</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">0.5&#8201;&#177;&#8201;0.05</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">0.2&#8201;&#177;&#8201;0.03</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AST (U/L)</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">15&#8201;&#177;&#8201;2</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">40&#8201;&#177;&#8201;5</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">25&#8201;&#177;&#8201;4</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cystatin C (mg/L)</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">0.6&#8201;&#177;&#8201;0.05</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">1.2&#8201;&#177;&#8201;0.1</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">0.8&#8201;&#177;&#8201;0.08</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.01</td></tr></tbody></table></table-wrap><p>Other Markers of inflammation and organ damage, showed in the control group, NF&#8208;&#954;B levels were 2&#8201;&#177;&#8201;0.5&#8201;pg/mL, while the Stanozolol&#8208;only group showed a significant increase to 12&#8201;&#177;&#8201;2&#8201;pg/mL (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), which was reduced to 6&#8201;&#177;&#8201;1&#8201;pg/mL in the Stanozolol + Allicin group (<italic toggle="yes">p</italic>&#8201;=&#8201;0.005). Similarly, iNOS levels were 0.8&#8201;&#177;&#8201;0.1&#8201;U/L in the control group, rising to 3.5&#8201;&#177;&#8201;0.4&#8201;U/L in the Stanozolol&#8208;only group (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), and decreasing to 1.5&#8201;&#177;&#8201;0.3&#8201;U/L with Allicin treatment (<italic toggle="yes">p</italic>&#8201;=&#8201;0.01). NO concentration followed the same trend, increasing from 15&#8201;&#177;&#8201;2&#8201;&#956;mol/L in the control group to 50&#8201;&#177;&#8201;5&#8201;&#956;mol/L with Stanozolol (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) and decreasing to 30&#8201;&#177;&#8201;4&#8201;&#956;mol/L with Allicin (<italic toggle="yes">p</italic>&#8201;=&#8201;0.01). Bcl&#8208;2 levels were significantly reduced in the Stanozolol&#8208;only group (8&#8201;&#177;&#8201;1&#8201;ng/mL) compared to the control (20&#8201;&#177;&#8201;3&#8201;ng/mL, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), but Allicin treatment restored it to 15&#8201;&#177;&#8201;2&#8201;ng/mL (<italic toggle="yes">p</italic>&#8201;=&#8201;0.005). Caspase&#8208;3 levels increased from 0.2&#8201;&#177;&#8201;0.05&#8201;ng/mL in the control to 1.2&#8201;&#177;&#8201;0.2&#8201;ng/mL with Stanozolol (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), decreasing to 0.6&#8201;&#177;&#8201;0.1&#8201;ng/mL with Allicin (<italic toggle="yes">p</italic>&#8201;=&#8201;0.005). TNF&#8208;&#945; levels showed a similar pattern, rising from 5&#8201;&#177;&#8201;1&#8201;pg/mL in the control to 18&#8201;&#177;&#8201;2&#8201;pg/mL with Stanozolol (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) and decreasing to 10&#8201;&#177;&#8201;1&#8201;pg/mL with Allicin (<italic toggle="yes">p</italic>&#8201;=&#8201;0.005). Finally, IL&#8208;1&#946; levels were 3&#8201;&#177;&#8201;0.5&#8201;pg/mL in the control, significantly increasing to 14&#8201;&#177;&#8201;1.5&#8201;pg/mL with Stanozolol (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) before being reduced to 7&#8201;&#177;&#8201;1&#8201;pg/mL with Allicin treatment (<italic toggle="yes">p</italic>&#8201;=&#8201;0.005). (Table&#160;<xref rid="ame270035-tbl-0005" ref-type="table">5</xref>).</p><table-wrap position="float" id="ame270035-tbl-0005" content-type="TABLE" orientation="portrait"><label>TABLE 5</label><caption><p>Inflammatory and organ damage markers &#8208; cellular indicators.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Marker</th><th align="left" valign="bottom" rowspan="1" colspan="1">Control group</th><th align="left" valign="bottom" rowspan="1" colspan="1">Stanozolol&#8208;only group</th><th align="left" valign="bottom" rowspan="1" colspan="1">Stanozolol&#8201;+&#8201;Allicin group</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8208;Value (control vs. stanozolol)</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8208;Value (stanozolol vs. allicin)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">NF&#8208;&#954;B (pg/mL)</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">2&#8201;&#177;&#8201;0.5</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">12&#8201;&#177;&#8201;2</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">6&#8201;&#177;&#8201;1</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">iNOS (U/L)</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">0.8&#8201;&#177;&#8201;0.1</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">3.5&#8201;&#177;&#8201;0.4</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">1.5&#8201;&#177;&#8201;0.3</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NO (&#956;mol/L)</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">15&#8201;&#177;&#8201;2</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">50&#8201;&#177;&#8201;5</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">30&#8201;&#177;&#8201;4</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bcl&#8208;2 (ng/mL)</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">20&#8201;&#177;&#8201;3</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">8&#8201;&#177;&#8201;1</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">15&#8201;&#177;&#8201;2</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Caspase&#8208;3 (ng/mL)</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">0.2&#8201;&#177;&#8201;0.05</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">1.2&#8201;&#177;&#8201;0.2</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">0.6&#8201;&#177;&#8201;0.1</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TNF&#8208;&#945; (pg/mL)</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">5&#8201;&#177;&#8201;1</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">18&#8201;&#177;&#8201;2</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">10&#8201;&#177;&#8201;1</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IL&#8208;1&#946; (pg/mL)</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">3&#8201;&#177;&#8201;0.5</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">14&#8201;&#177;&#8201;1.5</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">7&#8201;&#177;&#8201;1</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.005</td></tr></tbody></table></table-wrap></sec><sec id="ame270035-sec-0018"><label>3.5</label><title>Histopathological results</title><sec id="ame270035-sec-0019"><label>3.5.1</label><title>Control group histopathology</title><p>Figure&#160;<xref rid="ame270035-fig-0001" ref-type="fig">1</xref> presents the heart tissue structure in the control group, with Figure&#160;<xref rid="ame270035-fig-0001" ref-type="fig">1A</xref> (Hematoxylin and Eosin (H&amp;E), 100&#215;) showing intact myocardium, atrium, ventricle, heart valves, and endothelium, indicative of normal cardiac morphology. In Figure&#160;<xref rid="ame270035-fig-0001" ref-type="fig">1B</xref> (H&amp;E, 400&#215;), cardiac muscle cells (myocardium) and fibers are arranged in organized bundles, featuring a striated appearance and centrally located nuclei. Blood vessels maintain their normal structure with simple squamous endothelium. Figure&#160;<xref rid="ame270035-fig-0001" ref-type="fig">1C</xref> (H&amp;E, 400&#215;) further highlights the integrity of heart valves lined with endothelial cells and collagen&#8208;rich connective tissue, with visible red blood cells (RBCs), confirming preserved tissue architecture in the control group.</p><fig position="float" fig-type="FIGURE" id="ame270035-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Histopathological Examination of Heart Tissue from the Control Group. (A) Overview of heart structure showing (1) myocardium, (2) heart valve, (3) atrium, (4) ventricle, and (5) endothelium (H&amp;E, 100&#215;). (B) Detailed view of cardiac muscle cells (1) arranged in intersecting bundles with a striated appearance, (2) featuring centrally located spherical nuclei, and (3) blood vessels exhibiting simple squamous endothelium with elongated nuclei (H&amp;E, 400&#215;). (C) Heart valves lined with endothelial cells (1), surrounding connective tissue containing collagen and elastic fibers (2), and visible red blood cells (RBCs) (3) (H&amp;E, 400&#215;).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="AME2-8-1196-g001.jpg"/></fig></sec><sec id="ame270035-sec-0020"><label>3.5.2</label><title>Treated group histopathology</title><p>In contrast, Figure illustrates substantial structural damage in heart tissue sections from rabbits treated with stanozolol (Winstrol) at a dosage of 20&#8201;mg/kg/day. Figure&#160;<xref rid="ame270035-fig-0002" ref-type="fig">2A</xref> (H&amp;E, 100X) reveals compromised pericardium, myocardium, and blood vessels, indicating severe disruption. Figure&#160;<xref rid="ame270035-fig-0002" ref-type="fig">2B</xref> (H&amp;E, 100&#215;) shows ruptured squamous epithelial tissue within the endocardium, with damage extending to the myocardium and ventricular tissue. Figure&#160;<xref rid="ame270035-fig-0002" ref-type="fig">2C</xref> (H&amp;E, 400&#215;) displays pronounced myocardial fiber separation, with fibers appearing deeply eosinophilic and nuclei showing dense chromatin, suggestive of cell degeneration. Additionally, extensive tearing in the blood vessel walls points to vascular compromise, emphasizing the detrimental effect of stanozolol on cardiac tissue integrity and function.</p><fig position="float" fig-type="FIGURE" id="ame270035-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Histopathological Analysis of Cardiac Tissue from Rabbits Treated with Stanzolo (Winstrol) (20&#8201;mg/kg/day) for One Month. (A) Damage observed in (1) pericardium, (2) myocardium, and (3) blood vessels (H&amp;E, 100&#215;). (B) Rupture of squamous epithelial tissue in (1) endocardium, (2) myocardium, and (3) ventricle (H&amp;E, 100&#215;). (C) Separation of myocardial muscle fibers due to (1) tearing of heart muscle, with fibers appearing more eosinophilic than normal, and (2) dense, dark nuclei indicative of degeneration, alongside (3) damage to blood vessels characterized by wall tearing (H&amp;E, 400&#215;).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="AME2-8-1196-g003.jpg"/></fig></sec><sec id="ame270035-sec-0021"><label>3.5.3</label><title>Relative heart weight and collagen analysis</title><p>In the control group, the relative heart weight was 3.5&#8201;&#177;&#8201;0.2&#8201;g/kg, which significantly increased to 5.0&#8201;&#177;&#8201;0.3&#8201;g/kg in the Stanozolol&#8208;only group (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). Allicin treatment reduced this value to 4.0&#8201;&#177;&#8201;0.2&#8201;g/kg (<italic toggle="yes">p</italic>&#8201;=&#8201;0.01). Similarly, collagen deposition was 5&#8201;&#177;&#8201;1% in the control group, rising to 15%&#8201;&#177;&#8201;2% with Stanozolol administration (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) but decreasing to 8%&#8201;&#177;&#8201;1% following Allicin treatment (<italic toggle="yes">p</italic>&#8201;=&#8201;0.005) (Table&#160;<xref rid="ame270035-tbl-0006" ref-type="table">6</xref>).</p><table-wrap position="float" id="ame270035-tbl-0006" content-type="TABLE" orientation="portrait"><label>TABLE 6</label><caption><p>Cardiac morphometric and collagen analysis.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Parameter</th><th align="left" valign="bottom" rowspan="1" colspan="1">Control group</th><th align="left" valign="bottom" rowspan="1" colspan="1">Stanozolol&#8208;only group</th><th align="left" valign="bottom" rowspan="1" colspan="1">Stanozolol&#8201;+&#8201;Allicin group</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8208;Value (control vs. stanozolol)</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8208;Value (stanozolol vs. allicin)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Relative heart weight (g/kg)</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">3.5&#8201;&#177;&#8201;0.2</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">5.0&#8201;&#177;&#8201;0.3</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">4.0&#8201;&#177;&#8201;0.2</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Collagen deposition (%)</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">5&#8201;&#177;&#8201;1</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">15&#8201;&#177;&#8201;2</td><td align="char" char="&#xB1;" valign="top" rowspan="1" colspan="1">8&#8201;&#177;&#8201;1</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.005</td></tr></tbody></table></table-wrap><p>Analysis displayed in Figure&#160;<xref rid="ame270035-fig-0003" ref-type="fig">3</xref> demonstrates that Winstrol (Stanozolol) along with Allicin produces different impacts on cardiac tissue collagen deposition. Figure&#160;<xref rid="ame270035-fig-0003" ref-type="fig">3A</xref> findings reveal that Stanozolol treatment as a single substance leads to enhanced collagen accumulation thus exposing serious heart tissue fibrosis and cardiotoxicity damage. The drug Stanozolol leads to pathological remodeling in heart tissue because of inflammatory conditions combined with oxidative stress. The protective effects of Allicin become apparent when collagen deposition decreases in tissue samples given Stanozolol along with Allicin when compared to samples given Stanozolol alone as shown by panel Figure&#160;<xref rid="ame270035-fig-0003" ref-type="fig">3B</xref>. By being an anti&#8208;inflammatory and antioxidant agent Allicin demonstrates the ability to defend against the fibrotic changes caused by Stanozolol. The smallest amount of collagen exists in cardiac tissue from untreated animals who served as controls as shown by panel Figure&#160;<xref rid="ame270035-fig-0003" ref-type="fig">3C</xref>. This indicates that non&#8208;treated tissue did not exhibit pathological remodeling at baseline. These laboratory results establish that Allicin shows value as a treatment to fight against cardiac damage from Stanozolol medication.</p><fig position="float" fig-type="FIGURE" id="ame270035-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>(A) showed high collagen Deposition in the treated group with Stanozolol Only (H&amp;E, 400&#215;). (B) showed reduced collagen Deposition with treated Stanozolol and Allicin Group (H&amp;E, 100&#215;) and (C) was the lowest collagen Deposition in the control group (H&amp;E, 100&#215;).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="AME2-8-1196-g002.jpg"/></fig></sec></sec></sec><sec sec-type="discussion" id="ame270035-sec-0022"><label>4</label><title>DISCUSSION</title><p>The present study aimed to evaluate the physiological effects of allicin in preventing cardiac damage in rabbits treated with stanozolol (Winstrol). The results indicate significant alterations in various biochemical and histopathological markers, reflecting the impact of both the drug and the treatment regimen.</p><sec id="ame270035-sec-0023"><label>4.1</label><title>Cardiac damage markers</title><p>The chronic treatment of stanzolo also raises the cardiospecific troponin and CK similar to other observations where anabolic steroids are also known to cause myocardial damage.<xref rid="ame270035-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> Raised plasma troponin is evidence of cardiac cell injury while raised CK signifies myocardial necrosis.<xref rid="ame270035-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> However, the present treatment with allacin resulted in a significant decrease in both enzymes indicating that allacin may protect myocardial tissue, which is in concordance with the reports on the cardioprotective potentials of some phytochemicals.<xref rid="ame270035-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>
</p><p>Galectin&#8208;3 is a biomarker associated with heart fibrosis and inflammation. The stanozolol&#8208;only group demonstrated heightened Galectin&#8208;3 levels relative to the control group, signifying augmented fibrotic activity. The application of Allicin therapy showed significant success in lowering Galectin&#8208;3 levels, supporting its potential role in minimizing cardiac fibrosis.<xref rid="ame270035-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> Studies have proven that allicin shields hearts from fibrosis damage by neutralizing inflammatory proteins.<xref rid="ame270035-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> Stanozolol&#8208;only exposure resulted in the increased production of GDF&#8208;15 stress&#8208;responsive cytokine level when compared to the control group thus demonstrating more intensive cardiac stress. The levels of GDF&#8208;15 decreased with administration of allicin which indicates an additional protective benefit for the heart. Allicin reduces GDF&#8208;15 levels through its mechanism which modifies inflammatory pathways and oxidative stress regulation path.<xref rid="ame270035-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>
</p></sec><sec id="ame270035-sec-0024"><label>4.2</label><title>Oxidative stress and antioxidant capacity</title><p>Research shows that MDA measured higher levels in the stanozolol group which reveals increased lipid peroxidation together with oxidative damage.<xref rid="ame270035-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> Research has shown that stanozolol which is an anabolic&#8211;androgenic steroid increases MDA levels in the body thus causing elevated oxidative stress.<xref rid="ame270035-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> Experiments showed that MDA decreased in the allicin&#8208;treated group which confirms its antioxidant properties based on Nadeem et&#160;al.<xref rid="ame270035-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> Research shows that allicin from garlic has proven antioxidant effects as a sulfur compound that effectively neutralizes free radicals and lowers MDA levels that reflect oxidative stress.<xref rid="ame270035-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>
</p><p>Experimental data indicated that stanzolo treatment decreased antioxidant enzyme activity and this finding received support from Memudu and Dongo<xref rid="ame270035-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> who studied antioxidant depletion due to steroid use. Glutathione levels measured in Stanozolol&#8208;treated rats presented a significant reduction when compared to those of the control group thus showing compromised antioxidant defenses and enhanced vulnerability to oxidative damage. The group treated with stanozolol displayed considerably decreased catalase activity when contrasted to control levels which points to decreased hydrogen peroxide elimination ability. The treatment with allicin reestablished glutathione levels to similar levels as the control while simultaneously boosting catalase activity. The data shows that allicin establishes a protective antioxidant effect on the body. The consumption of allicin has been shown through recent research to raise glutathione and catalase levels which fight oxidative stress.<xref rid="ame270035-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> The antioxidant enzyme activity increases under allicin administration which protects cells from oxidative damage.<xref rid="ame270035-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>
</p></sec><sec id="ame270035-sec-0025"><label>4.3</label><title>Lipid profile</title><p>Stanozolol application leads to dyslipidemia through its effects on total cholesterol levels and LDL while reducing HDL amounts. Evidence from studies indicates that stanozolol administration produces cardiovascular risk factors because it both increases cholesterol production and makes hepatic lipase activity lower HDL levels.<xref rid="ame270035-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> The reported cardiovascular risk from stanozolol usage includes endothelial dysfunction and atherogenic pathway promotion according to Alyousif et&#160;al.<xref rid="ame270035-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>
</p><p>Allicin caused extensive lipid profile changes by reducing total cholesterol levels along with LDL cholesterol but increasing the HDL cholesterol. Allicin demonstrates its lipid&#8208;lowering properties through LDLR activity control together with PCSK9 inhibition which functions as a primary controller in cholesterol homeostasis.<xref rid="ame270035-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> Furthermore demonstrated to improve antioxidant activity is allicin, which lessens oxidative stress&#8208;induced lipid peroxidation<xref rid="ame270035-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> and indirectly benefits cardiovascular health.</p><p>These results are consistent with recent studies showing allicin's ability to prevent atherosclerotic risk and treat dyslipidemia. Through its anti&#8208;inflammatory and antioxidative qualities, allicin's benefits could go beyond lipid modification and help to protect hearts generally.<xref rid="ame270035-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="ame270035-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>
</p></sec><sec id="ame270035-sec-0026"><label>4.4</label><title>Inflammatory and organ damage markers</title><p>Key signals of systemic inflammation include CRP and IL&#8208;6. Reports associating anabolic steroids to increased inflammatory responses and oxidative stress, which can aggravate cardiovascular and renal risks, match the significant increase in CRP and IL&#8208;6 levels in the stanozolol&#8208;only group.<xref rid="ame270035-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="ame270035-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>
</p><p>Higher levels of the inflammatory index CRP and IL&#8208;6 were also observed in the stanozolol&#8208;treated group to the proposition that anabolic steroids could instigate infiltration of the body with inflammation.<xref rid="ame270035-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> Allacin treatment significantly reduced the CRP, evidently supporting a study which noted that natural compounds can reduce inflammation via the inhibition of cytokines.<xref rid="ame270035-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> Also reducing these markers with allicin co&#8208;administration demonstrates its strong anti&#8208;inflammatory action. By suppressing nuclear factor&#8208;kappa B (NF&#8208;&#954;B), allicin has been demonstrated to block pro&#8208;inflammatory cytokines, including IL&#8208;6, therefore reducing inflammation.<xref rid="ame270035-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="ame270035-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>
</p><p>As seen in the stanozolol&#8208;only group, elevated Procalcitonin levels represent a pro&#8208;inflammatory state generally linked with heart damage and systemic stress. This pro&#8208;inflammatory reaction can aggravate myocardial damage, therefore starting an inflammatory cycle with tissue destruction. The noted drop in Procalcitonin levels following allicin treatment emphasizes its possible function in altering inflammatory pathways most likely employing NF&#8208;&#954;B signaling's regulation of pro&#8208;inflammatory cytokines.<xref rid="ame270035-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>
</p><p>AST measurements in the stanozolol&#8208;only group demonstrate significant elevation that suggests hepatotoxicity similar to cardiac patient conditions due to either hepatic congestion or drug&#8208;caused oxidative stress. An increase in AST levels may serve as an indication of additional organ harm that occurs due to heart failure conditions. The reduction of AST levels by allicin amplifies its antioxidant properties that protect systemic homeostasis while decreasing liver damage.<xref rid="ame270035-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> Pressure injury to the heart commonly leads to renal dysfunction that presents itself through elevated Cystatin C levels because of cardiac&#8208;renal system interactions that medical experts call cardiorenal syndrome.<xref rid="ame270035-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> The renal damage from stanozolol exposure was more severe when administered alone thus leading to increased oxidative stress and renal dysfunction. In cardiology care, allicin has proven effective at reducing Cystatin C concentrations because it helps maintain antioxidant protection and leads to better renal results.<xref rid="ame270035-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>
</p><p>Research has proven that anabolic steroids boost NF&#8208;&#954;B signaling pathways which results in elevated inflammatory reactions.<xref rid="ame270035-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> The additional effect of anabolic steroids on iNOS and NO production creates endothelial dysfunction and oxidative stress conditions.<xref rid="ame270035-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> Studies by Hernandez&#8208;Rodriguez<xref rid="ame270035-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> confirm that anabolic steroids create an inflammatory pattern by escalating TNF&#8208;&#945; and IL&#8208;1&#946; cytokines which enhance systemic inflammation. Allicin has been reported in<xref rid="ame270035-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> to decrease inflammation through its action of inhibiting NF&#8208;&#954;B activation.<xref rid="ame270035-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> The study indicates that Allicin inhibits reactive oxygen species while suppressing iNOS expression to reduce oxidative stress.<xref rid="ame270035-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> According to Anarkooli et&#160;al.,<xref rid="ame270035-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> Allicin shows anti&#8208;apoptotic properties because it regulates mitochondrial pathways which leads to greater Bcl&#8208;2 activity while reducing Caspase&#8208;3 levels. The compound Allicin has been shown to limit pro&#8208;inflammatory cytokine release by blocking NF&#8208;&#954;B signaling mechanisms which demonstrates its pathway in decreasing systemic inflammation according to.<xref rid="ame270035-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>
</p></sec><sec id="ame270035-sec-0027"><label>4.5</label><title>Histopathological analysis</title><p>Many studies document extensive cardiac toxicity through hematoxylin and eosin staining and other histological tests in rabbits treated with stanozolol while this present evaluation validates existing investigations documenting steroid&#8208;induced cardiac tissue morphological changes.<xref rid="ame270035-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> The rabbits diagnosed with allacin throughout the trial displayed enhanced favorable cardiac tissue organization demonstrating the right direction toward cardiac protection. Because of these discoveries, researchers used previous research about natural products effectively protecting cardiac structure and functionality.<xref rid="ame270035-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref>
</p><p>The administration of Stanozolol led to a major increase in heart weight because anabolic steroids trigger cardiac hypertrophy through excessive fibrotic changes and elevated myocardial workload according to studies by Schimmel et&#160;al.<xref rid="ame270035-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref> Allicin treatment resulted in heart weight reduction indicating myocardial protection because this compound might decrease myocardial inflammatory response and oxidative stress.<xref rid="ame270035-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> Both collagen deposition levels and the role that Stanozolol&#8208;only use plays in cardiac fibrosis are verified by research documenting anabolic steroids boost TGF&#8208;beta (TGF&#8208;&#946;) signaling pathways to recreate extracellular matrix remodeling.<xref rid="ame270035-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> Previous findings showed that allicin decreases collagen buildup yet at the same time the study confirms its anti&#8208;fibrotic properties and TGF&#8208;&#946; suppression and downregulation of specific profibrotic genes.<xref rid="ame270035-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref>
</p></sec></sec><sec sec-type="conclusions" id="ame270035-sec-0028"><label>5</label><title>CONCLUSION</title><p>The present study&#8194;reveals that allicin provides remarkable cardioprotective effects against stanozolol&#8208;induced toxicity. It does this by reducing oxidative stress, suppressing inflammatory responses, and maintaining the integrity of myocardial structure. Allicin administration led to a notable decrease in biomarkers of cardiac injury (troponin, CK, Galectin&#8208;3, GDF&#8208;15), oxidative stress markers (MDA, glutathione, catalase), inflammatory cytokines (CRP, IL&#8208;6, NF&#8208;&#954;B, TNF&#8208;&#945;, IL&#8208;1&#946;) and improved lipid profiles.</p><p>The histopathological finding was confirmed to prevent cardiac remodeling, fibrosis, and reduced collagen deposition. These findings support the potential of allicin as a protective agent for cardiovascular health in the context of anabolic steroid&#8208;induced cardiotoxicity.</p></sec><sec id="ame270035-sec-0029"><label>6</label><title>LIMITATION OF THE STUDY</title><p>One of the limitations of this study is the restricted number of parameters analyzed. The inclusion of additional parameters could have provided a more comprehensive understanding of the Physiological effect of allicin to prevent cardiac damage.</p></sec><sec id="ame270035-sec-0035"><title>AUTHOR CONTRIBUTIONS</title><p>
<bold>Mohammed Hayder Asker:</bold> Conceptualization; data curation; formal analysis. <bold>Noor AL&#8208;Huda Salah AL&#8208;Zuhairy:</bold> Formal analysis; funding acquisition; methodology. <bold>Wassan Mhammed Husain:</bold> Software; supervision; validation; visualization. <bold>Mustafa Riyadh Abdullah:</bold> Resources; software; writing &#8211; original draft; writing &#8211; review and editing.</p></sec><sec id="ame270035-sec-0030"><title>FUNDING INFORMATION</title><p>The research and preparation of this manuscript were conducted without receiving any external funding or financial support. Every facet of the research, encompassing the gathering, processing, evaluation, and composition of the text, was carried out independently by the authors.</p></sec><sec sec-type="COI-statement" id="ame270035-sec-0031"><title>CONFLICT OF INTEREST STATEMENT</title><p>The authors of this publication affirm that they have no conflicting interests that could skew how the study findings are interpreted or presented. There are no personal or financial ties to any other people or organizations that may unintentionally affect the research described in this paper.</p></sec><sec id="ame270035-sec-1007"><title>ETHICS STATEMENT</title><p>Animal procedures approved by the Institutional Animal Care and Use Committee (IACUC) at Mustansiriyah University (Approval No. 42, 1/9/2024).</p></sec><sec id="ame270035-sec-0034"><title>CONSENT TO PARTICIPATE</title><p>Informed consent was obtained from all individual participants included in the study.</p></sec></body><back><ack id="ame270035-sec-1006"><title>ACKNOWLEDGMENTS</title><p>The authors would like to express their sincere gratitude to the College of Pharmacy, Mustansiriyah University, for providing the necessary facilities and support to carry out this research. Special thanks are also extended to the staff of the animal house for their assistance with animal care and experimental procedures.</p></ack><sec sec-type="data-availability" id="ame270035-sec-0033"><title>DATA AVAILABILITY STATEMENT</title><p>The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.</p></sec><ref-list content-type="cited-references" id="ame270035-bibl-0001"><title>REFERENCES</title><ref id="ame270035-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="ame270035-cit-0001"><string-name name-style="western"><surname>Baggish</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Weiner</surname><given-names>RB</given-names></string-name>, <string-name name-style="western"><surname>Kanayama</surname><given-names>G</given-names></string-name>, et&#160;al. <article-title>Cardiovascular toxicity of illicit anabolic&#8208;androgenic steroid use</article-title>. <source>Circulation</source>. <year>2017</year>;<volume>135</volume>(<issue>21</issue>):<fpage>1991</fpage>&#8208;<lpage>2002</lpage>. doi:<pub-id pub-id-type="doi">10.1161/circulationaha.116.026945</pub-id><pub-id pub-id-type="pmid">28533317</pub-id><pub-id pub-id-type="pmcid">PMC5614517</pub-id></mixed-citation></ref><ref id="ame270035-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="ame270035-cit-0002"><string-name name-style="western"><surname>Neto</surname><given-names>OB</given-names></string-name>, <string-name name-style="western"><surname>Da Mota</surname><given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>De Sordi</surname><given-names>CC</given-names></string-name>, et&#160;al. <article-title>Long&#8208;term anabolic steroids in male bodybuilders induce cardiovascular structural and autonomic abnormalities</article-title>. <source>Clin Auton Res</source>. <year>2017</year>;<volume>28</volume>(<issue>2</issue>):<fpage>231</fpage>&#8208;<lpage>244</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10286-017-0470-2</pub-id><pub-id pub-id-type="pmid">29019018</pub-id></mixed-citation></ref><ref id="ame270035-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="ame270035-cit-0003"><string-name name-style="western"><surname>Ahmed</surname><given-names>TH</given-names></string-name>, <string-name name-style="western"><surname>Raoof</surname><given-names>IB</given-names></string-name>, <string-name name-style="western"><surname>Mshemish</surname><given-names>BAR</given-names></string-name>. <article-title>Evaluation of nicorandil in treatment of induced pulmonary arterial hypertension in male rats</article-title>. <source>Al&#8208;Mustansiriya J Pharm Sci</source>. <year>2024</year>;<volume>24</volume>(<issue>3</issue>):<fpage>330</fpage>&#8208;<lpage>342</lpage>.</mixed-citation></ref><ref id="ame270035-bib-0004"><label>4</label><mixed-citation publication-type="miscellaneous" id="ame270035-cit-0004"><string-name name-style="western"><surname>De Souza</surname><given-names>FR</given-names></string-name>, <string-name name-style="western"><surname>Rochitte</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Silva</surname><given-names>DC</given-names></string-name>, et&#160;al. <article-title>Coronary inflammation by computed tomography pericoronary fat attenuation and increased cytokines in young male anabolic androgenic steroid users</article-title>. <year>2023</year>. doi:<pub-id pub-id-type="doi">10.36660/abc.20220822</pub-id><pub-id pub-id-type="pmcid">PMC10697680</pub-id><pub-id pub-id-type="pmid">37991119</pub-id></mixed-citation></ref><ref id="ame270035-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="ame270035-cit-0005"><string-name name-style="western"><surname>Torrisi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pennisi</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Russo</surname><given-names>I</given-names></string-name>, et&#160;al. <article-title>Sudden cardiac death in anabolic&#8208;androgenic steroid users: a literature review</article-title>. <source>Medicina (B Aires)</source>. <year>2020</year>;<volume>56</volume>(<issue>11</issue>):<elocation-id>587</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/medicina56110587</pub-id><pub-id pub-id-type="pmcid">PMC7694262</pub-id><pub-id pub-id-type="pmid">33158202</pub-id></mixed-citation></ref><ref id="ame270035-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="ame270035-cit-0006"><string-name name-style="western"><surname>Marwaha</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Papadakis</surname><given-names>M</given-names></string-name>. <article-title>Anabolic steroids in athletes: the interplay of hormones and inflammation leading to the heart's vulnerability</article-title>. <source>Eur J Prev Cardiol</source>. <year>2024</year>;<volume>31</volume>(<issue>12</issue>):<fpage>1477</fpage>&#8208;<lpage>1479</lpage>. doi:<pub-id pub-id-type="doi">10.1093/eurjpc/zwae253</pub-id><pub-id pub-id-type="pmid">39096270</pub-id></mixed-citation></ref><ref id="ame270035-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="ame270035-cit-0007"><string-name name-style="western"><surname>Memudu</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Dongo</surname><given-names>GA</given-names></string-name>. <article-title>A study to demonstrate the potential of anabolic androgen steroid to activate oxidative tissue damage, nephrotoxicity and decline endogenous antioxidant system in renal tissue of Adult Wistar Rats</article-title>. <source>Toxicol Rep</source>. <year>2023</year>;<volume>10</volume>:<fpage>320</fpage>&#8208;<lpage>326</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.toxrep.2023.02.010</pub-id><pub-id pub-id-type="pmid">36911166</pub-id><pub-id pub-id-type="pmcid">PMC9996376</pub-id></mixed-citation></ref><ref id="ame270035-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="ame270035-cit-0008"><string-name name-style="western"><surname>Chatterjee</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Chatterjee</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Ramavat</surname><given-names>A</given-names></string-name>. <article-title>Role and responsibility of allicin for the prevention of cardiovascular diseases: a systematic review</article-title>. <source>Res J Pharm Technol</source>. <year>2023</year>;<volume>16</volume>(<issue>12</issue>):<fpage>6055</fpage>&#8208;<lpage>6061</lpage>. doi:<pub-id pub-id-type="doi">10.52711/0974-360X.2023.00983</pub-id></mixed-citation></ref><ref id="ame270035-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="ame270035-cit-0009"><string-name name-style="western"><surname>Abdullah</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Alabassi</surname><given-names>HM</given-names></string-name>. <article-title>The potential influence of immune modulatory molecules (TGF&#8208;&#946;III and CTLA&#8208;4) in pathogenicity of PCOS</article-title>. <source>Karbala Int J Mod Sci</source>. <year>2024</year>;<volume>10</volume>(<issue>3</issue>):<fpage>2</fpage>. doi:<pub-id pub-id-type="doi">10.33640/2405-609X.3361</pub-id></mixed-citation></ref><ref id="ame270035-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="ame270035-cit-0010"><string-name name-style="western"><surname>Noushida</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Nayak</surname><given-names>RP</given-names></string-name>, <string-name name-style="western"><surname>Sultana</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>Cardioprotective effects of callicarpa Tomentosa leaf extract in Wistar albino rats against isoproterenol&#8208;induced myocardial necrosis: phytochemical analysis and in&#160;vitro antioxidant study</article-title>. <source>J King Saud Univ Sci</source>. <year>2024</year>;<volume>36</volume>(<issue>3</issue>):<elocation-id>103100</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.jksus.2024.103100</pub-id></mixed-citation></ref><ref id="ame270035-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="ame270035-cit-0011"><string-name name-style="western"><surname>Vieira</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Rossi</surname><given-names>WC</given-names></string-name>, <string-name name-style="western"><surname>Junior</surname><given-names>DR</given-names></string-name>, et&#160;al. <article-title>Effect of testosterone cypionate and stanozolol on the heart of young trained mice: a morphometric study</article-title>. <source>Steroids</source>. <year>2019</year>;<volume>145</volume>:<fpage>19</fpage>&#8208;<lpage>22</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.steroids.2019.02.011</pub-id><pub-id pub-id-type="pmid">30772437</pub-id></mixed-citation></ref><ref id="ame270035-bib-0012"><label>12</label><mixed-citation publication-type="miscellaneous" id="ame270035-cit-0012"><string-name name-style="western"><surname>Jain</surname><given-names>BV</given-names></string-name>, <string-name name-style="western"><surname>Pawar</surname><given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Chaudhari</surname><given-names>YA</given-names></string-name>, <string-name name-style="western"><surname>Shaikh</surname><given-names>MZ</given-names></string-name>. <article-title>Formulation and application of herbal preparation for bacterial pathogen</article-title>. sifisheriessciences.com <year>2023</year>. doi:<pub-id pub-id-type="doi">10.17762/sfs.v10i2S.796</pub-id></mixed-citation></ref><ref id="ame270035-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="ame270035-cit-0013"><string-name name-style="western"><surname>Sachdeva</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Dai</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Kloner</surname><given-names>RA</given-names></string-name>. <article-title>Functional and histological assessment of an experimental model of Takotsubo's cardiomyopathy</article-title>. <source>J Am Heart Assoc</source>. <year>2014</year>;<volume>3</volume>(<issue>3</issue>):<fpage>1</fpage>&#8208;<lpage>14</lpage>. doi:<pub-id pub-id-type="doi">10.1161/jaha.114.000921</pub-id><pub-id pub-id-type="pmcid">PMC4309094</pub-id><pub-id pub-id-type="pmid">24958782</pub-id></mixed-citation></ref><ref id="ame270035-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="ame270035-cit-0014"><string-name name-style="western"><surname>Da Cunha</surname><given-names>DF</given-names></string-name>, <string-name name-style="western"><surname>De Carvalho Da Cunha</surname><given-names>SF</given-names></string-name>, <string-name name-style="western"><surname>Reis</surname><given-names>M a D</given-names></string-name>, <string-name name-style="western"><surname>De Paula Antunes Teixeira</surname><given-names>V</given-names></string-name>. <article-title>Heart weight and heart weight/body weight coefficient in malnourished adults</article-title>. <source>Arq Bras Cardiol</source>. <year>2002</year>;<volume>78</volume>(<issue>4</issue>):<fpage>385</fpage>&#8208;<lpage>387</lpage>. doi:<pub-id pub-id-type="doi">10.1590/s0066-782x2002000400005</pub-id><pub-id pub-id-type="pmid">12011954</pub-id></mixed-citation></ref><ref id="ame270035-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="ame270035-cit-0015"><string-name name-style="western"><surname>Hammarsten</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Mair</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>M&#246;ckel</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lindahl</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Jaffe</surname><given-names>AS</given-names></string-name>. <article-title>Possible mechanisms behind cardiac troponin elevations</article-title>. <source>Biomarkers</source>. <year>2018</year>;<volume>23</volume>(<issue>8</issue>):<fpage>725</fpage>&#8208;<lpage>734</lpage>. doi:<pub-id pub-id-type="doi">10.1080/1354750x.2018.1490969</pub-id><pub-id pub-id-type="pmid">29976112</pub-id></mixed-citation></ref><ref id="ame270035-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="ame270035-cit-0016"><string-name name-style="western"><surname>Ho</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lyass</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Galectin&#8208;3, a Marker of Cardiac Fibrosis, Predicts Incident Heart Failure in the Community</article-title>. <source>Journal of the American College of Cardiology</source>. <year>2012</year>;<volume>60</volume>(<issue>14</issue>):<fpage>1249</fpage>&#8208;<lpage>1256</lpage>.<pub-id pub-id-type="pmid">22939561</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2012.04.053</pub-id><pub-id pub-id-type="pmcid">PMC3512095</pub-id></mixed-citation></ref><ref id="ame270035-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="ame270035-cit-0017"><string-name name-style="western"><surname>Sun</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Duan</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Lei</surname><given-names>M</given-names></string-name>. <article-title>Allicin protects against LPS&#8208;induced cardiomyocyte injury by activating Nrf2&#8208;HO&#8208;1 and inhibiting NLRP3 pathways</article-title>. <source>BMC Cardiovasc Disord</source>. <year>2023</year>;<volume>23</volume>:<elocation-id>410</elocation-id>.<pub-id pub-id-type="pmid">37596540</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12872-023-03442-1</pub-id><pub-id pub-id-type="pmcid">PMC10439633</pub-id></mixed-citation></ref><ref id="ame270035-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="ame270035-cit-0018"><string-name name-style="western"><surname>Gao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Qin</surname><given-names>G</given-names></string-name>, et&#160;al. <article-title>Therapeutic potentials of allicin in cardiovascular disease: advances and future directions</article-title>. <source>Chin Med</source>. <year>2024</year>;<volume>19</volume>:<elocation-id>93</elocation-id>.<pub-id pub-id-type="pmid">38956680</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13020-024-00936-8</pub-id><pub-id pub-id-type="pmcid">PMC11218272</pub-id></mixed-citation></ref><ref id="ame270035-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="ame270035-cit-0019"><string-name name-style="western"><surname>Dornelles</surname><given-names>RCM</given-names></string-name>, <string-name name-style="western"><surname>Oliveira</surname><given-names>LFS</given-names></string-name>, <string-name name-style="western"><surname>Silveira</surname><given-names>ST</given-names></string-name>. <article-title>Effects of anabolic&#8208;androgenic steroids on oxidative stress parameters: a systematic review</article-title>. <source>J Int Soc Sports Nutr</source>. <year>2021</year>;<volume>18</volume>(<issue>1</issue>):<fpage>1</fpage>&#8208;<lpage>14</lpage>.33388079
</mixed-citation></ref><ref id="ame270035-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="ame270035-cit-0020"><string-name name-style="western"><surname>Nadeem</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Kazmi</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Ullah</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Muhammad</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Anwar</surname><given-names>F</given-names></string-name>. <article-title>Allicin, an antioxidant and neuroprotective agent, ameliorates cognitive impairment</article-title>. <source>Antioxidants</source>. <year>2021</year>;<volume>11</volume>(<issue>1</issue>):<fpage>87</fpage>. doi:<pub-id pub-id-type="doi">10.3390/antiox11010087</pub-id><pub-id pub-id-type="pmid">35052591</pub-id><pub-id pub-id-type="pmcid">PMC8772758</pub-id></mixed-citation></ref><ref id="ame270035-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="ame270035-cit-0021"><string-name name-style="western"><surname>Ke</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>Y</given-names></string-name>. <article-title>Allicin attenuates UVB&#8208;induced photodamage of keratinocytes by inhibiting NLRP3 inflammasomes and activating the PI3K/Akt pathway</article-title>. <source>Arch Dermatol Res</source>. <year>2024</year>;<volume>317</volume>:<elocation-id>124</elocation-id>.<pub-id pub-id-type="pmid">39673634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00403-024-03599-5</pub-id><pub-id pub-id-type="pmcid">PMC11646263</pub-id></mixed-citation></ref><ref id="ame270035-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="ame270035-cit-0022"><string-name name-style="western"><surname>Panyod</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>WK</given-names></string-name>, <string-name name-style="western"><surname>Ho</surname><given-names>CT</given-names></string-name>, et&#160;al. <article-title>Diet supplementation with allicin protects against alcoholic fatty liver disease in mice by improving anti&#8208;inflammation and antioxidative functions</article-title>. <source>J Agric Food Chem</source>. <year>2016</year>;<volume>64</volume>(<issue>38</issue>):<fpage>7104</fpage>&#8208;<lpage>7113</lpage>.<pub-id pub-id-type="pmid">27584700</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jafc.6b02763</pub-id></mixed-citation></ref><ref id="ame270035-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="ame270035-cit-0023"><string-name name-style="western"><surname>Mahdy</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Abdu</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>El Baseer</surname><given-names>MAA</given-names></string-name>, <string-name name-style="western"><surname>Mohamed</surname><given-names>WA</given-names></string-name>. <article-title>Effect of thymoquinone and allicin on some antioxidant parameters in cancer prostate (PC3) and colon cancer (Caco2) cell lines</article-title>. <source>Sci J Al&#8208;Azhar Med Fac Girls</source>. <year>2020</year>;<volume>4</volume>(<issue>2</issue>):<fpage>85</fpage>&#8208;<lpage>96</lpage>.</mixed-citation></ref><ref id="ame270035-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="ame270035-cit-0024"><string-name name-style="western"><surname>Liu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ren</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>L</given-names></string-name>. <article-title>Anabolic androgenic steroids and cardiovascular risk: mechanistic insights and therapeutic implications</article-title>. <source>Front Cardiovasc Med</source>. <year>2021</year>;<volume>8</volume>:<elocation-id>634183</elocation-id>. Accessed December 29, 2024. doi:<pub-id pub-id-type="doi">10.3389/fcvm.2021.634183</pub-id></mixed-citation></ref><ref id="ame270035-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="ame270035-cit-0025"><string-name name-style="western"><surname>Alyousif</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Qureshi</surname><given-names>MZ</given-names></string-name>, <string-name name-style="western"><surname>Farooqi</surname><given-names>FA</given-names></string-name>, <string-name name-style="western"><surname>Al&#8208;Suhaimi</surname><given-names>EA</given-names></string-name>. <article-title>Effects of anabolic androgenic steroids on cardiovascular risk factors and biomarkers</article-title>. <source>Eur J Clin Investig</source>. <year>2022</year>;<volume>52</volume>(<issue>3</issue>):<elocation-id>e13711</elocation-id>. Accessed December 29, 2024. doi:<pub-id pub-id-type="doi">10.1111/eci.13711</pub-id><pub-id pub-id-type="pmid">34780064</pub-id><pub-id pub-id-type="pmcid">PMC9286413</pub-id></mixed-citation></ref><ref id="ame270035-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="ame270035-cit-0026"><string-name name-style="western"><surname>Sharma</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Yadav</surname><given-names>V</given-names></string-name>. <article-title>Allicin's therapeutic effects on hypercholesterolemia: a molecular perspective</article-title>. <source>J Cardiovasc Pharmacol Ther</source>. <year>2023</year>;<volume>28</volume>(<issue>5</issue>):<fpage>458</fpage>&#8208;<lpage>466</lpage>. doi:<pub-id pub-id-type="doi">10.1177/10742484231145820</pub-id></mixed-citation></ref><ref id="ame270035-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="ame270035-cit-0027"><string-name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></string-name>. <article-title>Antioxidant properties of allicin and its potential protective effects against cardiovascular diseases</article-title>. <source>Food Chem Toxicol</source>. <year>2022</year>;<volume>165</volume>:<fpage>113162</fpage>.35605717
</mixed-citation></ref><ref id="ame270035-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="ame270035-cit-0028"><string-name name-style="western"><surname>Bhol</surname><given-names>NK</given-names></string-name>, <string-name name-style="western"><surname>Bhanjadeo</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>AK</given-names></string-name>, et&#160;al. <article-title>The interplay between cytokines, inflammation, and antioxidants: mechanistic insights and therapeutic potentials of various antioxidants and anti&#8208;cytokine compounds</article-title>. <source>Biomed Pharmacother</source>. <year>2024</year>;<volume>178</volume>:<elocation-id>117177</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.biopha.2024.117177</pub-id><pub-id pub-id-type="pmid">39053423</pub-id></mixed-citation></ref><ref id="ame270035-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="ame270035-cit-0029"><string-name name-style="western"><surname>Wartalski</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Wiater</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Maciak</surname><given-names>P</given-names></string-name>, et&#160;al. <article-title>Anabolic steroids activate the NF&#8208;&#922;B pathway in porcine ovarian putative stem cells independently of the ZIP&#8208;9 receptor</article-title>. <source>Int J Mol Sci</source>. <year>2024</year>;<volume>25</volume>(<issue>5</issue>):<elocation-id>2833</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/ijms25052833</pub-id><pub-id pub-id-type="pmid">38474077</pub-id><pub-id pub-id-type="pmcid">PMC10932267</pub-id></mixed-citation></ref><ref id="ame270035-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="ame270035-cit-0030"><string-name name-style="western"><surname>Incalza</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>D'Oria</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Natalicchio</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Perrini</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Laviola</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Giorgino</surname><given-names>F</given-names></string-name>. <article-title>Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases</article-title>. <source>Vascul Pharmacol</source>. <year>2017</year>;<volume>100</volume>:<fpage>1</fpage>&#8208;<lpage>19</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vph.2017.05.005</pub-id><pub-id pub-id-type="pmid">28579545</pub-id></mixed-citation></ref><ref id="ame270035-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="ame270035-cit-0031"><string-name name-style="western"><surname>Hernandez&#8208;Rodriguez</surname><given-names>J</given-names></string-name>. <article-title>Tissue production of pro&#8208;inflammatory cytokines (IL&#8208;1, TNF and IL&#8208;6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant&#8208;cell arteritis</article-title>. <source>Br J Rheumatol</source>. <year>2003</year>;<volume>43</volume>(<issue>3</issue>):<fpage>294</fpage>&#8208;<lpage>301</lpage>. doi:<pub-id pub-id-type="doi">10.1093/rheumatology/keh058</pub-id><pub-id pub-id-type="pmid">14679293</pub-id></mixed-citation></ref><ref id="ame270035-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="ame270035-cit-0032"><string-name name-style="western"><surname>Liu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Joo</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>S</given-names></string-name>. <article-title>NF&#8208;&#954;B signaling in inflammation</article-title>. <source>Signal Transduct Target Ther</source>. <year>2017</year>;<volume>2</volume>(<issue>1</issue>):<elocation-id>17023</elocation-id>. doi:<pub-id pub-id-type="doi">10.1038/sigtrans.2017.23</pub-id><pub-id pub-id-type="pmid">29158945</pub-id><pub-id pub-id-type="pmcid">PMC5661633</pub-id></mixed-citation></ref><ref id="ame270035-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="ame270035-cit-0033"><string-name name-style="western"><surname>Koppula</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>IS</given-names></string-name>, <string-name name-style="western"><surname>Choi</surname><given-names>D</given-names></string-name>. <article-title>Reactive oxygen species and inhibitors of inflammatory enzymes, NADPH oxidase, and INOS in experimental models of Parkinson's disease</article-title>. <source>Mediat Inflamm</source>. <year>2012</year>;<volume>2012</volume>:<fpage>1</fpage>&#8208;<lpage>16</lpage>. doi:<pub-id pub-id-type="doi">10.1155/2012/823902</pub-id><pub-id pub-id-type="pmcid">PMC3346999</pub-id><pub-id pub-id-type="pmid">22577256</pub-id></mixed-citation></ref><ref id="ame270035-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="ame270035-cit-0034"><string-name name-style="western"><surname>Anarkooli</surname><given-names>IJ</given-names></string-name>, <string-name name-style="western"><surname>Sankian</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ahmadpour</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Varasteh</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Haghir</surname><given-names>H</given-names></string-name>. <article-title>Evaluation of BCL&#8208;2 expression and CASpaSe&#8208;3 in STZ&#8208;induced diabetic rats</article-title>. <source>J Diabetes Res</source>. <year>2008</year>;<volume>2008</volume>(<issue>1</issue>):<elocation-id>638467</elocation-id>. doi:<pub-id pub-id-type="doi">10.1155/2008/638467</pub-id><pub-id pub-id-type="pmcid">PMC2566751</pub-id><pub-id pub-id-type="pmid">18923682</pub-id></mixed-citation></ref><ref id="ame270035-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="ame270035-cit-0035"><string-name name-style="western"><surname>Yu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>H</given-names></string-name>. <article-title>Targeting NF&#8208;&#954;B pathway for the therapy of diseases: mechanism and clinical study</article-title>. <source>Signal Transduct Target Ther</source>. <year>2020</year>;<volume>5</volume>(<issue>1</issue>):<elocation-id>209</elocation-id>.<pub-id pub-id-type="pmid">32958760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-020-00312-6</pub-id><pub-id pub-id-type="pmcid">PMC7506548</pub-id></mixed-citation></ref><ref id="ame270035-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="ame270035-cit-0036"><string-name name-style="western"><surname>Kara</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ozcagli</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Kotil</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Alpertunga</surname><given-names>B</given-names></string-name>. <article-title>Effects of stanozolol on apoptosis mechanisms and oxidative stress in rat cardiac tissue</article-title>. <source>Steroids</source>. <year>2018</year>;<volume>134</volume>:<fpage>96</fpage>&#8208;<lpage>100</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.steroids.2018.02.004</pub-id><pub-id pub-id-type="pmid">29477345</pub-id></mixed-citation></ref><ref id="ame270035-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="ame270035-cit-0037"><string-name name-style="western"><surname>Kashef</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Elswaidy</surname><given-names>N</given-names></string-name>. <article-title>The possible role of allicin in ameliorating azithromycin induced cardiotoxicity in adult male albino rat: a histological and immunohistochemical study</article-title>. <source>Egypt J Histol</source>. <year>2021</year>;<volume>45</volume>(<issue>3</issue>):<fpage>863</fpage>&#8208;<lpage>874</lpage>. doi:<pub-id pub-id-type="doi">10.21608/ejh.2021.72878.1465</pub-id></mixed-citation></ref><ref id="ame270035-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="ame270035-cit-0038"><string-name name-style="western"><surname>Schimmel</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Ichimura</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Reddy</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Haddad</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Spiekerkoetter</surname><given-names>E</given-names></string-name>. <article-title>Cardiac fibrosis in the pressure overloaded left and right ventricle as a therapeutic target</article-title>. <source>Front Cardiovasc Med</source>. <year>2022</year>;<volume>9</volume>:<elocation-id>886553</elocation-id>. doi:<pub-id pub-id-type="doi">10.3389/fcvm.2022.886553</pub-id><pub-id pub-id-type="pmid">35600469</pub-id><pub-id pub-id-type="pmcid">PMC9120363</pub-id></mixed-citation></ref><ref id="ame270035-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="ame270035-cit-0039"><string-name name-style="western"><surname>Ma</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>Allicin improves cardiac function by protecting against apoptosis in rat model of myocardial infarction</article-title>. <source>Chin J Integr Med</source>. <year>2016</year>;<volume>23</volume>(<issue>8</issue>):<fpage>589</fpage>&#8208;<lpage>597</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11655-016-2523-0</pub-id><pub-id pub-id-type="pmid">27412589</pub-id></mixed-citation></ref><ref id="ame270035-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="ame270035-cit-0040"><string-name name-style="western"><surname>Chung</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hsu</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Liou</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>. <article-title>Androgen attenuates cardiac fibroblasts activations through modulations of transforming growth factor&#8208;&#946; and angiotensin II signaling</article-title>. <source>Int J Cardiol</source>. <year>2014</year>;<volume>176</volume>(<issue>2</issue>):<fpage>386</fpage>&#8208;<lpage>393</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ijcard.2014.07.077</pub-id><pub-id pub-id-type="pmid">25125004</pub-id></mixed-citation></ref><ref id="ame270035-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="ame270035-cit-0041"><string-name name-style="western"><surname>Salehi</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Zucca</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Orhan</surname><given-names>IE</given-names></string-name>, et&#160;al. <article-title>Allicin and health: a comprehensive review</article-title>. <source>Trends Food Sci Technol</source>. <year>2019</year>;<volume>86</volume>:<fpage>502</fpage>&#8208;<lpage>516</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.tifs.2019.03.003</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>